0001322505 false 0001322505 2022-06-16 2022-06-16 iso4217:USD xbrli:shares iso4217:USD xbrli:shares
 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): June 16, 2022

 

ALBIREO PHARMA, INC.

(Exact name of registrant as specified in its charter)

  

Delaware
(State or other jurisdiction of
incorporation)		   001-33451
(Commission File
Number)		   90-0136863
(IRS Employer
Identification No.)

 

53 State Street, 19th Floor
Boston, Massachusetts
(Address of principal executive offices)		   02109
(Zip Code)

 

(857) 254-5555

Registrant’s telephone number, including area code

 

Not applicable

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which
registered		  
Common Stock   ALBO   The Nasdaq Capital Market  

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company  ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ¨

 

 

 

 

 

 

Item 5.07 Submission of Matters to a Vote of Security Holders.

 

On June 16, 2022, Albireo Pharma, Inc. (the “Company”) held its 2022 Annual Meeting of Stockholders (the “Annual Meeting”). At the Annual Meeting, the stockholders: (1) elected each of David Chiswell, Ph.D. and Davey S. Scoon to the Company’s Board of Directors as a Class III director for a term of three years to serve until the 2025 annual meeting of stockholders and until his respective successor is elected and qualified or until his earlier death, resignation or removal (“Election of Directors”); and (2) ratified the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2022 (“Auditor Ratification”). A more complete description of each of these matters is set forth in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on April 21, 2022. 

 

The number of votes cast in favor or against or withheld by the stockholders and, where applicable, the number of abstentions and the number of broker nonvotes on each of the foregoing matters are set forth below.

 

1. Election of Directors

 

Nominee  Shares
Voted
For		   Shares Voted
to Withhold
Authority		   Broker
Nonvotes		 
David Chiswell, Ph.D.   10,252,529    274,590    2,234,685 
Davey S. Scoon   9,825,125    701,994    2,234,685 

 

2. Auditor Ratification

 

Shares
Voted For		   Shares Voted
Against		   Shares
Abstaining		   Broker
Nonvotes		 
12,754,534   5,689   1,581   - 

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  ALBIREO PHARMA, INC.
   
Date: June 17, 2022 /s/ Ronald H.W. Cooper
  Name: Ronald H.W. Cooper
  Title: President and Chief Executive Officer

 

3 

 

Albireo Pharma (NASDAQ:ALBO)
Historical Stock Chart
Von Mär 2024 bis Apr 2024 Click Here for more Albireo Pharma Charts.
Albireo Pharma (NASDAQ:ALBO)
Historical Stock Chart
Von Apr 2023 bis Apr 2024 Click Here for more Albireo Pharma Charts.